Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA acts on heart failure application for Forest's Bystolic

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

The agency did not approve the full additional indication for treatment of stable chronic heart failure as requested in Forest's nebivolol sNDA, the firm announced Feb. 23, but the firm did get some of the trial data included in labeling. VP-Investor Relations Frank Murdolo explained in an email exchange that FDA did issue a supplement approval, but narrowed the approval to inclusion of additional safety information based on the CHF study. Labeling now includes a heart failure section under "special populations" that reports that in a placebo-controlled trial of 2,128 patients over 70 years of age with CHF, no worsening of heart failure was seen with nebivolol compared to placebo. Since hypertension (for which Bystolic is approved) may lead to heart failure, it is important to note that if a patient is treated for hypertension with Bystolic and develops heart failure, Bystolic does not make the condition worse, Murdolo said. Forest continues to work with FDA on a plan to move forward in CHF; the advisory committee recommended a non-inferiority study against other beta blockers (1"The Pink Sheet," Jan. 18, 2010)
Advertisement
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS004364

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel